In Vitro Diagnostic (UKCA) Products

Targeted NGS panels for sensitive cancer detection enabling early diagnosisand longitudinal monitoring of disease.

Ultrasensitive sequencing methods play a pivotal role in driving forward precision oncology, advancing approaches to cancer diagnosis and treatment. The challenge is to detect rare mutations and genetic alterations with unprecedented accuracy to gain invaluable insight into a patient's unique tumor profile.

Explore Nonacus innovative NGS solutions which confidently identify mutations down to 0.1% VAF, ushering in a new era of personalized targeted therapies enabling earlier cancer diagnosis, more informed treatment decisions, and hyper-sensitive relapse monitoring.

Clinical Oncology Products

Technology-Galeas-Bladder 1066x768

GALEAS™ Bladder (UKCA)

A comprehensive biomarker test delivering cystoscopy-level accuracy for all grades and stages of bladder cancer from a simple urine sample.

With sensitivity of >90%, GALEAS Bladder offers a non-invasive, sample-to-report, molecular triage for hematuria patients, allowing urologists to make informed decisions as to whether further investigation is required.

Learn more

GALEAS™ Tumor (UKCA)

A clinically validated panel designed in parallel with variant calling software for comprehensive genomic profiling of solid tumors.

GALEAS Tumor profiles key DNA biomarkers across 519 genes streamlining the detection of SNVs, INDELs, CNVs, TMB and MSI into a single workflow. Cloud-based bioinformatic pipelines enable rapid integration into any laboratory.

Learn more
Untitled (260 x 197 px) (1)

Resources

sprite

Publications

sprite

Protocols

sprite

Panel Design Tool

Are you ready to harness the power of targeted oncology panels?

Contact us